Top Markets
#1 ADO Protocol ADO Protocol +193.12%
#2 Islamic Coin Islamic Coin +155.43%
#3 GoPlus Security GoPlus Security +48.69%
#4 GAIB AID GAIB AID +24.67%
#5 Starpower Starpower +17.54%
#6 Chia Chia +15.11%
#7 Casper Network Casper Network +13.73%
#8 Verus Coin Verus Coin +13.56%
#9 o1.exchange o1.exchange +12.82%
#10 Pons Pons +12.26%
Coin of the day
ADO Protocol ADO Protocol
Settings
Language
ENGLISH
Currency
USD
Theme
Bharat Immunologicals & Biologicals Corporation Limited Bharat Immunologicals & Biologicals Corporation Limited

Bharat Immunologicals & Biologicals Corporation Limited

BIBCL
Rank in Stocks #33476
Bharat Immunologicals & Biologicals Corp. Ltd. operates as a biotechnology... Bharat Immunologicals & Biologicals Corp. Ltd. operates as a biotechnology enterprise, primarily involved in the development and manufacture of pharmaceutical goods. Its offerings include vital products such as oral polio vaccines, zinc tablets, comprehensive diarrhea management kits, and ready-to-consume therapeutic foods. The firm organizes its operations into several key divisions: Oral Polio Vaccine (OPV), Zinc Tablets, BIB VIT, and BIBSANIT. Founded on March 10, 1989, the company's main office is situated in Bulandshahr, India.
Share Price
$0.17558081
Market Cap
$7.58M
Change (1 day)
-0.25%
Change (1 year)
-30.30%
Country
IN
Trade Bharat Immunologicals & Biologicals Corporation Limited (BIBCL)

Category

Healthcare
Revenue for Bharat Immunologicals & Biologicals Corporation Limited (BIBCL)
Revenue in Aug 2026 TTM: 0
According to Bharat Immunologicals & Biologicals Corporation Limited latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Bharat Immunologicals & Biologicals Corporation Limited from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 $2.54B -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
 - -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 - -
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
 - -
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
 $830.81M -
US